Trial · NCT07070479
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
NCT07070479, Phase 2, Recruiting, Ming-Yuan Chen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial. Trials, record NCT07070479. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07070479
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
- NCT number
- NCT07070479
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 208 participants, estimated
- Lead sponsor
- Ming-Yuan Chen
- Conditions
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Interventions
- Ivonescimab, Nimotuzumab, Irinotecan liposome, S-1, Mitoxantrone Hydrochloride Liposome, PD-1 Inhibitors
- First posted
- 2025-07-17
- Last updated
- 2025-09-18
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | 1 year | Defined as the proportion of patients whose tumors shrink to complete response (CR) or partial response (PR) and remain for a certain period of time according to RECIST 1.1 |
| Secondary | Progression-free Survival (PFS) | 1 year | PFS is defined as the time interval from randomization to the observation of disease progression or death from any cause |
| Secondary | Overall Survival (OS) | 1 year | OS is defined as the time interval from randomization to death from any cause |
| Secondary | Duration of Response (DOR) | 1 year | DOR is defined as time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death |
| Secondary | Disease Control Rate (DCR) | 1 year | DCR is defined as the percentage of patients who have achieved CR, PR and SD to a therapeutic intervention |
| Secondary | Adverse Events Reporting | 1 year | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Secondary | Health-related Quality of Life | 1 year | Changes from baseline in patient-reported quality of life scores assessed every 2 cycles using the EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, version C30). The scores range from 0 to 100, with higher scores indicating a better quality of life outcome. |
| Secondary | Head and Neck Cancer-Specific Quality of Life | 1year | Changes from baseline in head and neck cancer-specific symptoms and functions assessed every 2 cycles using the EORTC QLQ-H\&N35 module (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Head and Neck Cancer Module). The scores range from 0 to 100, with higher scores indicating a better quality of life outcome and lower scores indicating worse symptoms or functions. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07070479
GET https://conductscience.org/api/trials/v1/NCT07070479/registered